Marimastat in recurrent colorectal cancer: Exploratory evaluation of biological activity by measurement of carcinoembryonic antigen

British Journal of Cancer

Volumn 79, Issue 3-4, 1999, Pages 509-514

  Primrose, J N ^a   Bleiberg, H ^b   Daniel, F ^c   Van Belle, S ^d   Mansi, J L ^e   Seymour, M ^f   Johnson, P W ^f   Neoptolemos, J P ^g   Baillet, M ^h   Barker, K ^h   Berrington, A ^h   Brown, P D ^h   Millar, A W ^h   Lynch, K P ^h  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b JULES BORDET INSTITUTE   (Belgium)

^c PLYMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e ST GEORGE S HOSPITAL   (United Kingdom)

^f ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^g QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^h British Biotech Pharmaceuticals Ltd   (United Kingdom)

Author keywords

Carcinoembryonic antigen; Colorectal cancer; Marimastat; Metalloproteinase inhibitors

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; ASCITES; BACKACHE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; HUMAN; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENT CANCER; SEROLOGY; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXAMIC ACIDS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; PILOT PROJECTS; RECURRENCE;

EID: 0032934107     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690079     Document Type: Article

References (31)

1. Allen-Mersh TG, Kemeny N, Niedzwiecki D, Shurgot B and Daly JM (1987) Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer. Gut 28: 1625-1629
2. An Z, Wang X, Willmott N, Chander SK, Tickle S, Docherty AJ, Mountain A, Millican AT, Morphy R, Porter RJ, Epemolu RO, Kubota T, Moossa AR and Hoffman RM (1997) Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastasis 15: 184-195
3. Beckett RP, Davidson AH, Drummond AH, Huxley P and Whittaker M (1996) Recent advances in matrix metalloproteinase research. Drug Dev Today I: 16-26
4. Brown PD and Giavazzi R (1995) Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 6: 967-974
5. Fountzilas G, Gossios K, Zisiadis A, Svarna E, Skarlos D and Pavlidis N (1996) Prognostic variables in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy. Med Ped Oncol 26: 305-317
6. Gijbels K, Masure S, Carton H and Opdenakker G (1992) Gelatinase in cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 41: 29-34
7. Gold P and Freedman SO (1965) Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and adsorption techniques. J Exp Med 121: 439
8. Gordon JL, Drummond AH and Galloway WA (1993) Metalloproteinase inhibitors as therapeutics. Clin Exp Rheum 11: S91-S94
9. Gray ST, Yun K, Motoori T and Kuys YM (1993) Interstitial collagenase gene expression in colonic neoplasia. Am J Pathol 143: 663-671
10. Hida J, Yasutomi M, Shindoh K, Kitaoka M, Fujimoto K, Ieda S, Machidera N, Kubo R, Morikawa E, Inufus H, Watatani M and Okuno K (1996) Second-look operation for recurrent colorectal cancer based on carcinoembryonic antigen and imaging techniques. Dis Colon Rectum 39: 74-79
11. Ishikawa T, Ichikawa Y, Mitsuhashi M, Momiyama N, Chishima T, Tanaka K, Yamaoka H, Miyazakic K, Nagashima Y, Akitaya T and Shimada H (1996) Matrilysin is associated with progression of colorectal tumor. Cancer Lett 107: 5-10
12. Kleiner DJ and Stetler-Stevenson WG (1993) Structural biochemistry and activation of matrix metalloproteinases. Curr Opinions Cell Biol 5: 891-897
13. r 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 51: 439-444
14. Liotta LA and Stetler-Stevenson WG (1990) Metalloproteinases and cancer invasion. Semin Cancer Biol 1: 99-106
15. Matrisian LM (1990) Metalloproteinases and their inhibitors in matrix remodelling. Trends Genet 6: 121-125
16. Millar AW, Brown PD, Moore J, Galloway WA, Cornish AG, Lenehan TJ and Lynch KP (1998) Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol 45: 21-26
17. Minton JP, Hoehn JL, Gerber DM, Horsley JS, Connolly DP, Salwan F, Fletcher WS, Cruz Jr AB, Gatchell FG and Oviedo M (1985) Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 55: 1284-1290
18. Nakayama T, Watanabe M, Teramoto T and Kitajima M (1997) Slope analysis of CA19-9 and CEA for predicting recurrence in colorectal cancer patients. Anticancer Res 17: 1379-1382
19. Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A, Lynch K, Rasmussen H, Kerr D, Cox D and Millar A (1998) Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 4: 1101-1109
20. Newell KJ, Witty JP, Rodgers WH and Matrisan LM (1994) Expression and localisation of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog 10: 199-206
21. O'Byrne EM, Parker DT, Roberts ED, Goldberg RL, MacPherson LJ, Blancuzzi V, Wilson D, Singh HN, Ludewig R and Ganu VS (1995) Oral administration of a matrix metalloproteinase inhibitor, CGS 27023A, protects the cartilage proteoglycan matrix in a partial meniscectomy model of osteoarthritis in rabbits. Inflammation Res 44: S117-S118
22. Quentmeier A, Schlag P, Smok M and Herfarth C (1990) Re-operation for recurrent colorectal cancer: the importance of early diagnosis for resectability and survival. Eur J Surg Oncol 16: 319-325
23. Rosenberg GA (1995) Matrix metalloproteinases in brain injury. J Neurotrauma 12: 833-842
24. Saarialho-Kere UK, Vaalamo M, Puolakkainen P, Airola K, Parks WC and Karjalainen-Lindsberg ML (1996) Enhanced expression of matrilysin, collagenase and stromelysin-1 in gastrointestinal ulcers. Am J Pathol 148: 519-526
25. Schwartz MK (1992) Enzymes as prognostic markers and therapeutic indicators in patients with cancer. Clin Chim Acta 206: 77-82
26. Sugarbaker PH, Zamcheck N and Moore FDK (1976) Assessment of serial carcinoembryonic antigen (CEA) in postoperative management of colon and rectal cancer. Cancer 38: 2310-2315
27. Wang X, Fu X, Brown PD, Crimmin MJ and Hoffman RM (1994) Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumour growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 54: 4726-4728
28. Ward U, Primrose JN, Finan PJ, Perren TJ, Selby P, Purves DA and Cooper EH (1993) The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br J Cancer 67: 1132-1135
29. Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD and Hardcastle JD (1995) Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 55: 3629-3633
30. Zeng SZ, Huang Y, Cohen AM and Guillem JG (1996) Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 14: 3133-3140
31. r 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 53: 140-146